In HTLV-1 carriers, visual disturbances emerging shortly after the initiation of antithyroid drug therapy should not be automatically attributed to thyroid-associated ophthalmopathy; clinicians must differentiate HTLV-1-associated uveitis (HAU) to ensure appropriate management. Severe adverse reactions, including hepatotoxicity and granulocytopenia, can occur with antithyroid drugs, such as methimazole and propylthiouracil, and may arise sequentially, highlighting the significant therapeutic challenge and the necessity of careful monitoring in this population. HTLV-1 carriers diagnosed with one autoimmune disorder are at increased risk of developing polyautoimmunity, such as subsequent Sjögren's syndrome, necessitating comprehensive and long-term multisystem surveillance.
Kasamatsu et al. (Wed,) studied this question.